Jacobs Levy Equity Management, Inc Travere Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $25.8 Billion
- Q4 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 2,174,213 shares of TVTX stock, worth $49.3 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
2,174,213
Previous 1,590,377
36.71%
Holding current value
$49.3 Million
Previous $22.2 Million
70.23%
% of portfolio
0.15%
Previous 0.09%
Shares
17 transactions
Others Institutions Holding TVTX
# of Institutions
213Shares Held
94.1MCall Options Held
1.2MPut Options Held
778K-
Black Rock Inc. New York, NY7.64MShares$173 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.36MShares$167 Million1.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.74MShares$153 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.97MShares$113 Million3.46% of portfolio
-
Macquarie Group LTD Australia, C34.26MShares$96.5 Million0.09% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.45B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...